{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:37:49Z","timestamp":1776659869898,"version":"3.51.2"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>We have previously shown that refractory neuroendocrine tumors can respond to moderate doses of chemoradiotherapy. We completed a dose-escalation phase I\/II trial combining hepatic arterial (HA) chemotherapy, chemoembolization, and dose-escalated whole liver radiotherapy to determine the maximum safe dose of radiation that could be delivered and to make a preliminary assessment of response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>From 2002 to 2009, 19 patients with symptomatic neuroendocrine liver metastases who failed somatostatin analog therapy were enrolled. HA fluorodeoxyuridine, leucovorin, and streptozotocin were delivered, as concurrent whole liver radiotherapy was dose escalated from 24 to 32 Gy in 2 Gy fractions, with a target rate of dose-limiting grade \u22653 radiation-induced liver disease of 10%. Eight weeks later, for patients without grade \u22653 liver or grade \u22654 any toxicity, a 72-hour infusion of HA fluorodeoxyuridine and leucovorin was given, followed by transarterial chemoembolization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eleven patients completed the entire protocol and received 24 to 32 Gy. No patients developed radiation-induced liver disease; 7 had grade 3 to 4 transiently increased liver function tests, and 4 had other grade 4 toxicities. Three patients (14%) had partial response, 16 (84%) stable disease. Median freedom from local progression and overall survival were 35.3 and 54.6 months, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Thirty-two in 2 Gy daily fractions can be delivered safely when combined with HA chemotherapy and subsequent transarterial chemoembolization. However, although objective responses were observed, this combination was not significantly better than our prior approaches. Further treatment intensification strategies, including individualized dose escalation for radiation-tolerant livers, and improved radiosensitization should be investigated, along with improved systemic therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000276","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T23:13:29Z","timestamp":1455750809000},"page":"326-331","source":"Crossref","is-referenced-by-count":2,"title":["Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine\/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine\/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases"],"prefix":"10.1097","volume":"41","author":[{"given":"Mark","family":"Shilkrut","sequence":"first","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Sapir","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela","family":"Hanasoge","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Schipper","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P.","family":"Normolle","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Ben-Josef","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Ensminger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore S.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Feng","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230905","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"R2-20230905","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"R3-20230905","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1055-3207(02)00076-5","article-title":"Hepatic surgery for metastases from neuroendocrine tumors","volume":"12","author":"Sarmiento","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"R4-20230905","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/lt.20702","article-title":"Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival","volume":"12","author":"van Vilsteren","year":"2006","journal-title":"Liver Transpl"},{"key":"R5-20230905","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/msy.2001.117377","article-title":"Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors","volume":"130","author":"Yao","year":"2001","journal-title":"Surgery"},{"key":"R6-20230905","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/07357909909032856","article-title":"Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma","volume":"17","author":"Kim","year":"1999","journal-title":"Cancer Invest"},{"key":"R7-20230905","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ijrobp.2008.12.044","article-title":"Radiotherapy for pancreatic neuroendocrine tumors","volume":"75","author":"Contessa","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20230905","first-page":"88","article-title":"A phase I\/II trial of chemoembolization after hepatic arterial FUDR\/LV and whole liver radiotherapy","volume":"1","author":"McGinn","year":"1998","journal-title":"Cancer Ther"},{"key":"R9-20230905","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/cdd.1983.1.63","article-title":"Hepatic arterial streptozocin: a clinical pharmacologic study in patients with liver tumors","volume":"1","author":"Gyves","year":"1983","journal-title":"Cancer Drug Deliv"},{"key":"R10-20230905","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"key":"R11-20230905","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"R12-20230905","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0360-3016(02)02846-8","article-title":"Analysis of radiation-induced liver disease using the Lyman NTCP model","volume":"53","author":"Dawson","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20230905","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1200\/JCO.2005.01.5354","article-title":"Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies","volume":"23","author":"Ben-Josef","year":"2005","journal-title":"J Clin Oncol"},{"key":"R14-20230905","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-011-0248-1","article-title":"Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres","volume":"35","author":"Paprottka","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R15-20230905","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-20230905","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"R17-20230905","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"R18-20230905","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1078-0432.CCR-07-0955","article-title":"Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer","volume":"14","author":"Manegold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R19-20230905","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","article-title":"Real-world study of everolimus in advanced progressive neuroendocrine tumors","volume":"19","author":"Panzuto","year":"2014","journal-title":"Oncologist"},{"key":"R20-20230905","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/COC.0b013e3181b0c298","article-title":"Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity","volume":"33","author":"Oh","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"R21-20230905","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijrobp.2009.07.1730","article-title":"Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus","volume":"78","author":"Koo","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-20230905","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijrobp.2012.02.037","article-title":"Prediction of liver function by using magnetic resonance-based portal venous perfusion imaging","volume":"85","author":"Cao","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20230905","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2217\/pme.10.5","article-title":"Adaptive trial of personalized radiotherapy for intrahepatic cancer","volume":"7","author":"Normolle","year":"2010","journal-title":"Per Med"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201804000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:33:24Z","timestamp":1693956804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201804000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000276","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}